Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 19/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 18/20 | 0.52 |
| ▸ | CDK2 | P24941 | 8/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.52 |
| ▸ | CDK4 | P11802 | 7/20 | 0.52 |
| ▸ | CCND1 | P24385 | 7/20 | 0.52 |
| ▸ | CDK1 | P06493 | 6/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.52 |
| ▸ | CDK3 | Q00526 | 6/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 4/20 | 0.44 |
| ▸ | CCNH | P51946 | 3/20 | 0.44 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21946485 | 1.00 | CDK9 (0.52) | CDK9CCNT1CDK2CCNA1CDK4 | |
| SCHEMBL21877616 | 0.95 | CDK9 (0.52) | CDK9CCNT1CDK2CCNA1CDK4 | |
| SCHEMBL21877634 | 0.95 | CDK9 (0.52) | CDK9CCNT1CDK2CCNA1CDK4 | |
| SCHEMBL21877637 | 0.95 | CDK9 (0.52) | CDK9CCNT1CDK2CCNA1CDK4 | |
| SCHEMBL21946490 | 0.93 | CDK9 (0.46) | CDK9CCNT1CDK2CCNA1CDK4 | |
| SCHEMBL21877626 | 0.93 | CDK9 (0.46) | CDK9CCNT1CDK2CCNA1CDK4 | |
| SCHEMBL21877594 | 0.91 | CDK9 (0.54) | CDK9CCNT1CDK2CCNA1CDK4 | |
| SCHEMBL21877680 | 0.86 | CCNT1 (0.58) | CDK9CCNT1CDK2CCNA1CDK4 | |
| SCHEMBL21946413 | 0.86 | CCNT1 (0.58) | CDK9CCNT1CDK2CCNA1CDK4 | |
| SCHEMBL21947317 | 0.83 | CCNT1 (0.74) | CDK9CCNT1CDK2CCNA1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845754-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200131189-A1 | Compounds, Compositions, and Methods for Modulating CDK9 Activity | IGNOTA LABS LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131189-A1 | Compounds, Compositions, and Methods for Modulating CDK9 Activity | CDK9, CDK19, CDK7 | CDK9 1/4885CCNT1 55/4885CDK2 8/4885 |
| US-11845754-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | CDK9, CDK19, CDK7 | CDK9 1/4885CCNT1 40/4885CDK2 9/4885 |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | CDK9, CDK19, CDK7 | CDK9 1/4885CCNT1 55/4885CDK2 8/4885 |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | CDK9, CDK19, CDK7 | CDK9 1/4885CCNT1 40/4885CDK2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.